Ultraviolet light in combination with other therapies for vitiligo: Synergy or necessity? - 05/12/20
Doi : 10.1016/j.jaad.2020.08.120
Danielle Peterson, MD, Brett A. King, MD, PhD ⁎ 
Department of Dermatology, Yale University School of Medicine, New Haven, Connecticut
∗Correspondence to: Brett King, MD, PhD, Department of Dermatology, Yale University School of Medicine, PO Box 208059, New Haven, CT 06520Department of DermatologyYale University School of MedicinePO Box 208059New HavenCT06520
Le texte complet de cet article est disponible en PDF.
| Funding sources: Dr King has received funding support from The Ranjini and Ajay Poddar Resource Fund for Dermatologic Diseases Research. |
|
| Conflict of interest: Dr King has a patent for treating vitiligo with Janus kinase inhibitors in combination with phototherapy; is an investigator for Concert Pharmaceuticals Inc, Eli Lilly and Company, and Pfizer Inc; is a consultant to and/or has served on advisory boards for Aclaris Therapeutics, Arena Pharmaceuticals, Bristol Meyers Squibb, Concert Pharmaceuticals Inc, Dermavant Sciences, Eli Lilly and Company, Pfizer Inc, and Viela Bio; and is on speaker's bureau for Regeneron and Sanofi Genzyme. Dr Peterson has no conflicts of interest to declare. |
|
| IRB approval status: Not applicable. |
|
| Reprints not available from the authors. |
© 2020
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 84 - N° 1
P. e63-e64 - janvier 2021 Retour au numéro
Article précédent
- Authors' reply to the comment “Treatment considerations for patients with pemphigus during the COVID-19 pandemic”
- Hadir Shakshouk, Maryam Daneshpazhooh, Dedee F. Murrell, Julia S. Lehman
- Employing geriatric principles in the management of nonmelanoma skin cancers
- Michael A. Liu, Jannett Nguyen
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?